Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at the AAPS 2022 PHARMSCI 360

2022-10-10
|
Page View:

Join Medicilon at the AAPS 2022 PHARMSCI 360.webp

Troubled by your current problems with drug discovery? Meet Medicilon at AAPS 2022 PHARMSCI 360! It kicks off on October 16, 2022 in Boston. Our EVP Dr. Xuedong Dai  and Dr. Zhenrong Guo will be present in person at booth No. 808Our American team will also be there. Maybe Medicilon can help you solve your current problem and become a partner of choice!


About AAPS 2022 PHARMSCI 360

Founded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is an international professional scientific organization with more than 11,000 members in academia, industry, government and other research institutions to advance the ability of pharmaceutical scientists to develop products and therapeutics to improve global health. The members of AAPS are mainly from the fields of pharmacology, biopharmaceutical or pharmaceutical research. The aim of AAPS is to provide a platform for the exchange of pharmaceutical science knowledge. To promote the development of pharmaceutical science; Encourage high standards of education in pharmaceutical sciences, health professions and related disciplines. This time, AAPS 2022 PHARMSCI 360 will be held in Boston, USA from October 16 to 19, 2022. The conference will cover drug discovery, design, analysis, and development and so on.

 

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.


 

Dr. Xuedong Dai, EVP of International R&D Services of Medicilon. Ph.D. in Organic Chemistry and Postdoctoral at MIT, has been deeply involved in the research and development of chemical drugs for central nervous system diseases, infectious diseases and tumor diseases for more than 20 years.  Dr. Dai has a deep understanding and rich experience in the process of drug discovery, including the identification and optimization of seed compounds, and the development of high-quality clinical candidate compounds.  


Medicilon Drug Discovery Services

Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.

The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!


EVP of International R&D Services of Medicilon. Ph.D. in Organic Chemistry and Postdoctoral at MIT, has been deeply involved in the research and development of chemical drugs for central nervous system diseases, infectious diseases and tumor diseases for more than 20 years.  Dr. Dai has a deep understanding and rich experience in the process of drug discovery, including the identification and optimization of seed compounds, and the development of high-quality clinical candidate compounds.  



Dr. Zhenrong Guo, EVP of Pharmacy. professor-level senior engineer, Ph.D. from University of Western Ontario, Canada; MBA, Fairleigh Dickinson University, USA; Post-Doctoral Fellow at Monell Chemical Senses Center and University of California, Berkeley, USA.  Dr. Guo was the vice chairman of the Pharmaceutical Engineering Professional Committee of Zhejiang Pharmaceutical Association, and is currently an adjunct professor at Zhejiang University of Technology.

 

Medicilon Pharmaceutical Research

At present, CMC research layout of Medicilon: with about 6000+ square meters of process amplification laboratory, 4000+ square meters of preparation research and development and GMP production facilities, can provide chemical process research, drug synthesis process optimization, pharmaceutical process amplification, preparation process amplification, chemical project research and development outsourcing services, high quality and effect of new drug research and development!


Services:
❖Research on preformulation

❖Research on formulation process
❖Research on preparation quality
❖Laboratory-scale test of preparation
❖Pilot-scale test of preparation
❖GMP-based clinical sample production and packaging
❖Preparation stability test
❖Consistency evaluation


Share:
Return
Relevant newsRelevant news